Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Harvard Business School
Farmers Insurance
Baxter
Fish and Richardson
Argus Health
Cipla
Cantor Fitzgerald

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021500

« Back to Dashboard

NDA 021500 describes EMTRIVA, which is a drug marketed by Gilead and is included in two NDAs. It is available from three suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the EMTRIVA profile page.

The generic ingredient in EMTRIVA is emtricitabine. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the emtricitabine profile page.
Summary for 021500
Tradename:EMTRIVA
Applicant:Gilead
Ingredient:emtricitabine
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 021500
Medical Subject Heading (MeSH) Categories for 021500
Suppliers and Packaging for NDA: 021500
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMTRIVA emtricitabine CAPSULE;ORAL 021500 NDA Excella GmbH 46014-0601 46014-0601-1 30 CAPSULE in 1 BOTTLE, PLASTIC (46014-0601-1)
EMTRIVA emtricitabine CAPSULE;ORAL 021500 NDA State of Florida DOH Central Pharmacy 53808-0801 53808-0801-1 30 CAPSULE in 1 BLISTER PACK (53808-0801-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Jul 2, 2003TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 2, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:May 4, 2021Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Sep 9, 2021Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021500

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead EMTRIVA emtricitabine CAPSULE;ORAL 021500-001 Jul 2, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Gilead EMTRIVA emtricitabine CAPSULE;ORAL 021500-001 Jul 2, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Gilead EMTRIVA emtricitabine CAPSULE;ORAL 021500-001 Jul 2, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
McKinsey
Argus Health
Cerilliant
AstraZeneca
Healthtrust
US Department of Justice
Queensland Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.